CTRI/2009/091/000929已完成2 期
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 164
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Histologically confirmed non-GCB DLBCL - done by central lab
- •-CD20 positive disease
- •-At least 1 measurable or assessable site of disease
排除标准
- •-Prior anti-neoplastic (including unconjugated therapeutic antibodies) experimental or radiation therapy
- •-Peripheral neuropathy or neuropathic pain of grade 2 or worse
- •- Prior treatment with VELCADE
研究者
相似试验
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell LymphomaEUCTR2009-012280-34-CZJanssen-Cilag International N.V.164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphomaon-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 14.0Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012280-34-BEJanssen-Cilag International N.V.164
进行中（未招募）
1 期
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia - Lumiliximab in combination with FCR in the treatment of relapsed CRelapsed Chronic Lymphocytic Leukemia (CLL)MedDRA version: 9.1Level: LLTClassification code 10008956Term: Chronic lymphatic leukaemiaEUCTR2006-002987-24-FRBiogen Idec Ltd280
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Safety and Efficacy of Lumiliximab in Combination with Fludarabine, Cyclophosphamide, and Rituximab Versus Fludarabine, Cyclophosphamide, and Rituximab Alone in Subjects with Relapsed Chronic Lymphocytic Leukemia - Lumiliximab in combination with FCR in the treatment of relapsed CRelapsed Chronic Lymphocytic Leukemia (CLL)MedDRA version: 8.1Level: LLTClassification code 10008956Term: Chronic lymphatic leukaemiaEUCTR2006-002987-24-PTBiogen Idec Ltd627
进行中（未招募）
不适用
A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination ofVELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone(VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, andPrednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal CenterB-Cell Subtype of Diffuse Large B-Cell Lymphomaon-Germinal Center B-Cell Subtype of Diffuse Large B-Cell LymphomaMedDRA version: 14.1Level: PTClassification code 10012818Term: Diffuse large B-cell lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-012280-34-DEJanssen-Cilag International N.V.164